Warfarin cohort (reference) Apixaban cohort Warfarin cohort (reference) Dabigatran cohort Warfarin cohort (reference) Rivaroxaban cohort
N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD
Sample size 6310 100% 6310 100% 2342 100% 2342 100% 8055 100% 8055 100%
Age 71.2 8.7 71.2 8.9 69.7 8.9 69.6 8.9 70.7 8.8 70.7 8.8
Gender
Male 2859 45.3% 2862 45.4% 1143 48.8% 1142 48.8% 3689 45.8% 3703 46.0%
US geographic region*
Northeast 1091 17.3% 1064 16.9% 455 19.4% 461 19.7% 1377 17.1% 1413 17.5%
North Central 1785 28.3% 1783 28.3% 622 26.6% 649 27.7% 2387 29.6% 2347 29.1%
South 2592 41.1% 2594 41.1% 911 38.9% 899 38.4% 3082 38.3% 3118 38.7%
West - - 852 13.5% - - 321 13.7% - - 1158 14.4%
Other - - 17 0.3% - - 12 0.5% - - 19 0.2%
Race (only for Humana and Medicare)
White 4462 88.4% 4451 88.2% 1513 87.4% 1505 86.9% 5573 87.9% 5579 88.0%
Black 399 7.9% 411 8.1% 162 9.4% 157 9.1% 502 7.9% 505 8.0%
Other 184 2.9% 183 2.9% 56 2.4% 69 2.9% 263 3.3% 254 3.2%
Baseline comorbidity
Deyo-Charlson Comorbidity Index 4.5 3.0 4.4 3.0 4.1 2.9 4.0 2.9 4.3 3.0 4.3 3.0
1|2|3|4|5|6|7|8